Lorlatinib in ALK-Positive Lung Cancer: When Efficacy Is Not the Limiting Factor
Abstract
Lorlatinib offers unmatched systemic and central nervous system control in ALK-positive lung cancer, but its clinical value is determined not only by efficacy but also by how well adverse effects are anticipated and managed in real-world practice.
Fields of Study & Subjects
Lung Cancer Treatments and Mutations
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 5 March 2026
- Language
- EN
- Document type
- Dataset